Rank #1490PTCT

PTC Therapeutics, Inc.

$69.90

1.41% (Daily)

Market Cap

$5.61B

Revenue

$1.78B

Rank by MCap

#1490

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Matthew B. Klein F.A.C.S., M.D., M.S.

Headquarters

Warren, NJ

Employees

939

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat sp...